Colistimethate
These agents have been reported to be susceptible to Gram-negative bacteria in the lower respiratory tract and urinary tract infections and in Pseudomonas aeruginosa infections of lung in patients of cystic fibrosis.
2.5 to 5mg/kg/day in 2 to 4 divided doses, i.v. or i.m
Known hypersensitivity to colistimethate or colistin or polymyxin. Patients with myasthenia gravis.
Crosses placental barrier so given in pregnancy only after outweighing the potential benefit against the potential risk to fetus. Secreted in breast milk so administered to lactating mothers only on specific indication. Warnings: To be used with caution in patients with porphyria.
Neurotoxicity, Nephrotoxicity, Hyprsensitivity and Skin rash, Respiratory arrest, Skin infection.
These agents are not administered concomitantly with other drugs having potential nephrotoxic effects (e.g. amphotericin B, sodium citrate, cephalothin, polymyxin B, vancomycin, aminoglycoside antibiotics such as gentamicin, tobramycin, paromomycin). Anaesthetics and muscle relaxants (tubocurarine, succinylcholine, gallamine, ether) enhance the neuromuscular blocking effects of colistimethate and are to be used with extreme caution.
